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Background The Second Generation Antipsychotics (SGAs) are associated with metabolic disturbances. Diabetic Ketoacidosis (DKA) is a rare, but potentially fatal sign of acute glucose metabolism dysregulation, which may be associated with the use of SGAs. This study aims to review published reports of patients with schizophrenia and antipsychotic drug-induced DKA, focusing on the effective management of both conditions 
Methods  Using a pre-defined search strategy we searched PubMed and EMBASE from their inception to July, 2016. The search terms were related to ‘diabetic ketoacidosis’ and ‘antipsychotic medication’. Case reports, case series and reviews of case series written in English language were included in the review.
Results 65 reports were analysed. In the majority of the patients who developed antipsychotic-induced DKA one or more suspected antipsychotic medications were discontinued. In five cases a re-challenge test was trialed, and in only one case it resulted in the elevation of blood glucose. The majority was subsequently treated with a different SGA in combination with insulin/oral hypoglycemic agents; althouhg about a third of patients had a complete resolution of symptoms or could control diabetes with diet only at the point of discharge. 
Conclusion Patients taking antipsychotic medications should be regularly screened for insulin resistance and educated about potential complications of antipsychotic medications. This will allow clinicians to individualize treatment decisions and reduce iatrogenic contribution to morbidity and mortality. To achieve best treatment outcomes, antipsychotic-induced DKA should be treated jointly by psychiatry and endocrinology teams. 





The Second Generation Antipsychotics (SGAs) are considered as the first line treatment for schizophrenia spectrum disorders. In addition to their effectiveness in treating psychotic symptoms, most SGAs are associated with significant weight gain and the development of glucose intolerance, thus causing diabetes mellitus, metabolic syndrome, and overall increased risk of cardiovascular morbidity and mortality (1, 2, 3). 

Diabetic ketoacidosis (DKA) is an acute complication of diabetes that mainly occurs in patients with type 1 diabetes, but it is not uncommon in patients with type 2 diabetes. This condition is a complex disordered metabolic state characterized by hyperglycemia, ketoacidosis, and ketonuria. With prompt treatment, diabetic ketoacidosis can be corrected without any complications developing. If left untreated, the condition can be life-threatening. Diabetic ketoacidosis (DKA) was once considered a hallmark feature that would differentiate individuals with type 1 diabetes mellitus from those with type 2 diabetes mellitus, although reports of DKA occurring in patients with type 2 diabetes mellitus were described as well (4). Epidemiologic studies have estimated that DKA-related hospitalizations have increased over the past two decades, reaching the rates of 32.4 per 1,000 among people younger than 45 years, 3.3 among people aged 45–64 years, and 1.4 among people aged 65 years or older (5) 

Interestingly, in schizophrenia DKA is often the first sign of antipsychotic-induced diabetes mellitus among patients. For example, Henderson et al (2007) (6) showed that the incidence of diabetes presenting as DKA in this population is more than 10-fold higher than in the general population. Among those with pre-existing diabetes mellitus, the rate is 30-fold higher (7). Other risk factors include polypharmacy, olanzapine monotherapy, clozapine monotherapy, male gender, and middle age (45 – 60 years) (8). Antipsyhotic-induced DKA has been associated with 13% mortality rate (9,10).
The management of DKA (irrespective of whether it is part of type 1 or type 2 diabetes mellitus) consists of intravenous insulin therapy with concomitant glucose administration when plasma glucose levels fall below 300 mg/dL (16.7 mmol/L), sufficient volume and electrolyte replacement, and careful attention to identification and management of associated problems, such as acute pancreatitis and infection (4). Despite all this, no recommendations exist for management of DKA in psychiatric patients. Given the long-term nature of psychiatric treatments, as well as high mortality rates of antipsychotic-induced DKA, this condition represents a compelling treatment challenge throughout the course of illness. 





Using a pre-defined search strategy we searched PubMed and EMBASE from their inception to July, 2016. The search terms included ‘diabetic ketoacidosis’, ‘antipsychotics’, ‘atypical antipsychotics’, ‘first generation antipsychotics’, ‘second generation antipsychotics’, ‘clozapine’, ‘olanzapine’, ‘risperidone’, ‘quetiapine’, ‘ziprasidone’, ‘aripiprazole’, ‘paliperidone’, ‘amisulpride’, and ‘haloperidol’.  We also conducted hand searches of key journals and publications of experts in the field for potentially relevant articles. Papers reporting clinical cases of diabetic ketoacidosis associated with the use of antipsychotic agents were included. Only papers published in English language were included. 
All potential studies were exported into reference management software. Next, duplicates were removed and we conducted the initial screening of titles and abstracts for inclusion against the eligibility criteria. The full text of articles meeting the criteria were obtained and reviewed. Data were extracted on patients characteristics (sociodemographic and clinical status) and psychiatric pharmacotherapy associated with DKA before and after the occurrence of DKA.

Using these key words, we selected 168 titles. After reading the article titles, we selected 140 abstracts in English language articles from the period 1994-2015. Out of these abstracts we selected 83 case reports and reviews of case series and included them into the review. A total of 18 cases were excluded due to lack of provided information: in 11 cases there was no record of AP therapy after DKA and in 7 cases patients deceased. After applying the inclusion and exclusion criteria, 65 reports were included in this review. The final list included 44 case reports and 6 case series (Table 1, Figure 1)

3.Results
Sociodemographic and clinical characteristics of the patients are summarized in the Supplementary Table (10-59).

3.1. Antipsychotic medication
Results of treatment options after antipsychotic-induced DKA are summarized in Figure 1. 
[Insert Figure 1.] 

In the majority of reported cases (N=58), DKA was associated with SGA monotherapy: olanzapine (N=26), clozapine (N=17), risperidone (N=6), aripiprazole (N=6), quetiapine (N=3). In majority of these cases, the suspected SGA was withdrawn from treatment after detecting DKA. Subsequently, patients were put on different antipsychotic medications, as shown in Table 2. [Insert Table 1.]

In five cases a re-challenge test was trialed. In two cases, clozapine was restarted 24 days and two months after the DKA, respectively. However, in both cases, clozapine was again discontinued due to elevation of serum glucose levels. In one case clozapine was restarted and continued due to treatment resistance to others antipsychotics. Every subsequent discontinuation of clozapine due to the patient’s non-compliance resulted in glucose levels normalization, followed by the elevation of glucose levels after clozapine re-introduction. In one case olanzapine was restarted after one month and discontinued after three days due to elevation of serum glucose levels. Blood glucose levels stabilized with oral hypoglycemic therapy (OHT). The patient was prescribed with clozapine which again led to elevated glucose serum levels, regardless of the increased dose of OHT. One successful re-challenge was described in the patient treated with risperidone where DKA developed shortly after perospirone hydrochloride (a novel serotonin-dopamine antagonist) was added to risperidone. Risperidone was restarted in monotherapy 2 weeks after the DKA was detected while insulin therapy was gradually replaced with diet.

In seven cases DKA was associated with polypharmacy and authors reported the discontinuation of one or even both suspected agent (Figure 1). 

3.2. Antidiabetic treatment 

After the acute treatment of DKA, 19 patients completely recovered and or 10 patients were able to control diabetes mellitus with diet only. Among the patients who were discharged without antidiabetic treatment, in one case hypergliceamia was reported after six months, but the circumstances in which this occurred were not reported. However, the majority of patients needed antidiabetic treatment with insulin (N=30), oral hypoglicemic agent (N=9) or even both (4) at the time of hospital discharge regardless of the change in antipsychotic treatment. Among those who were discharged from the hospital with antidiabetic medication, the majority still needed antidiabetic treatment (N=24) in the follow up period, 5 patients had a complete resolution of diabetes mellitus and the rest were lost in the follow up (N=14). 






This literature review reveals that clinicians tend to employ several strategies when treating patients with antipsychotic – induced DKA: 1) Acute management includes discontinuation of the suspected SGA agent and introduction of antidiabetic agents (insulin, OHT) and lifestyle changes (e.g. diabetic diet); 2) Post-DKA management includes switching to a different AP medication with lower propensity or re-introduction of the same AP medication. Most patients require continuous antidiabetic treatment. In several cases both AP and antidiabetic treatment were discontinued.

The re-introduction of the same AP medication seems the least optimal as it is associated with a significant risk of relapse of diabetes mellitus or DKA. In the few cases where re-challenge was tried on with the same therapeutic agent or the one from the similar pharmacological group (olanzapine, clozapine), glucose dysregulation was observed despite the use of insulin/ or oral antidiabetic. Furthermore, in the majority of cases, the maintenance of the same antipsychotic therapy required insulin therapy in multiple daily injection therapy. Apart from being very demanding on patients, there are numerous risks associated with such therapy (e.g. hypoglycemia, ketoacidosis, chronic complications etc.), especially given the low compliance of patients with major psychiatric disorders (60). Therefore, the decision to re-introduce the same antipsychotic together with insulin or oral antidiabetic should requires a careful risk assessment taking into account the patient’s psychiatric status, possibility to achieve remission with another antipsychotic, risk of new DKA, and the possibility to maintain normoglycemia. Given the periodic nature of schizophrenia and bipolar disorder, the option to discontinue both AP and antidiabetic treatment is not suggested either, as the risk of relapse of psychiatric symptoms is significant (61).

Our results show that emergency treatment with insulin and fluid resuscitation led to complete recovery of antipsychotic-induced DKA in the majority of cases (62-66). However, this was found only when the suspected drug was discontinued. According to recently published reports, DKA does not seem to be a temporary, time limited medical event. According to Guenette et al. (10), after acute treatment of DKA, 36 % patient had complete resolution of symptoms and required no treatment; 14 % controlled diabetes mellitus with diet; and 50 % relied on insulin, oral hypoglycemic agents, or both (8). Similarly, we found that the majority of the reported patients, needed continuation of antidiabetic therapy at the time of discharge. This might reflect a certain degree of β-cell failure which possibly persists after the antipsychotic-induced DKA, although as to the best of our knowledge, no data were published on this topic.

Our findings indicate that patients with glucose intolerance needing antipsychotic treatment require interdisciplinary management provided by psychiatry and diabetology teams. In line with the American Diabetes Association/American Psychiatric Association consensus conference (2016) (67) recommendations for metabolic monitoring of patients receiving atypical antipsychotics, psychiatrists should perform the following: obtain data on personal and family history of diabetes mellitus, screen at baseline and regularly monitor physical and laboratory indicators including waist circumference, glucose and lipids in blood, regularly assess side effects, and educate patients and their caregivers about antipsychotic-induced side-effects. Diabetologists should diagnose and treat acute DKA following the treatment protocol (intravenously and later subcutaneously application of insulin), and make recommendations based on the type of diabetes. After DKA is diagnosed, the preferred treatment options include: 1) exclusion of suspected agent in acute DKA; 2) application of the standard therapy for DKA; 2) given the morbidity and mortality associated with DM, as well as the need for long term treatment, switching to another SGA with lower propensity to DKA, unless it is already proven that the change of the basic antipsychotic will lead to significant deterioration of the patient’s psychiatric status; 3) slow reduction of insulin dose and possibly omission of insulin based on glycemic values (first reduce prandial and then basal insulin); 4) If there are no contraindications for metformin, the maximal dose of 2g per day bid divided should be introduced until HbA1c reaches less than 6%. At that point we recommend reducing the daily dose of metformin by half, and monitoring HbA1c in the next 3 to 6 months. If HbA1c is lower than 6%, metformin should be excluded from therapy. Recommendations are summarized in Table 2.














1.	Daumit GL, Goff DC, Meyer JM et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2007;105:175–187. 
2.	De Hert M, Detraux J, Van Winkel R et al.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114–126.
3.	 Hedenmalm K, Hagg S, Stahl et al. Glucose intolerance with atypical antipsychotics. Drug Saf 2002;25:1107–1116.
4.	Newton CA, Raskin P. Diabetic Ketoacidosis in Type 1 and Type 2 Diabetes Mellitus: Clinical and Biochemical Differences. Arch Intern Med 2004;164:1925-1931.
5.	Centers for Disease Control,Division of Diabetes Translations,  Diabetes Surveillance Report. Available at: https://www.cdc.gov/diabetes/statistics/dkafirst/fig4.htm.
6.	Henderson DC, Cagliero E, Copeland PM et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007;68:533-541. 
7.	Lipscombe LL, Austin PC, Alessi-Severini S et al. Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data. Schizophr Res 2014;154:54-60.
8.	Vuk A, Rojnic Kuzman M, Baretic M et al. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. Psych Danubina 2017 (accepted for publication).
9.	Efstathiou SP, Tsiakou AG, Tsioulos DI et al. A mortality prediction model in diabetic ketoacidosis. Clin Endocrinol 2002;57:595–601.
10.	Guenette M, Hahn M, Cohn T et al. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology (Berl) 2013;226:1-12. 
11.	Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care 1994;22:176-7.
12.	Kostakoglu AE, Yazici KM, Erbas T et al. Ketoacidosis as a side-effect of clozapine: a case report. Acta Psychiatr Scand 1996;93:217–218. 
13.	Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment. Am J Psychiatry 1996;153:737–738.
14.	Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. Postgrad Med J 1998; 74:493–494. 
15.	Pierides M. Clozapine monotherapy and ketoacidosis. Br J Psychiatry 1997;171:90–91.
16.	Popli AP, Konicki PE, Jurjus GJ. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-111. 
17.	Wirshing DA, Spellberg BJ, Erhart SM et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778–783.
18.	Colli A, Cocciolo M, Francobandiera F et al. Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care 1999;22:176–177.
19.	Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999;22:1002–1003.
20.	Goldstein LE, Sporn J, Brown S et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443.
21.	Mohan D, Gordon H, Hindley N et al. Schizophrenia and diabetes mellitus. Br J Psychiatry J 1999;174:180–181.
22.	Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis. Aust N Z J Psychiatry 1999;33:120–121.
23.	Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000;41:369–370.
24.	Rigalleau V, Gatta B, Bonnaud S et al. Diabetes as a result of atypical anti-psychotic drugs —a report of three cases. Diabet Med 2000;17:484– 486.
25.	Avram AM, Patel V, Taylor HC et al. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001;35:1381–1387. 
26.	Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001;14:278–282.
27.	Nicolai J, Smith SJ, Keunen RW. Simultaneous side effects of both clozapine and valproate. Intensive Care Med 2001;27:943. 
28.	Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother 2001;35:1556–1558. 
29.	Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 2001;138:936–938.
30.	Wirshing DA, Pierre JM, Eyeler J et al. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001;50:148−149.
31.	Johnson RP, Al-Taher MT, Madlock LE. Increasing insulin dose for olanzapine-related diabetes. Am J Psychiatry 2002;159:150–151.
32.	Waldman JC, Yaren S. Atypical antipsychotics and glycemia: a case report. Can J Psychiatry 2002;47:686–687.
33.	Wilson DR, D’Souza L, Sarkar N et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003;59:1–6. 
34.	Tavakoli SA, Arguisola MS. Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine. South Med J 2003; 96:729–730.
35.	Tsuchiyama N, Ando H, Ota T et al. Modulating effects of olanzapine on the development of diabetic ketoacidosis. Diabet Med 2004;21:300–301. 
36.	Ananth J, Johnson KM, Levander EM et al. Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate. J Clin Psychiatry 2004;65:724. 
37.	Meyer JM, Lekband SG, Loh CC et al. Quetiapine-induced diabetes with metabolic acidosis. Int Clin Psychopharmacol 2004;19:169 –171.
38.	Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005;22:1440–1443. 
39.	Dibben CR, Kalavalapalli SS, Linnington HE et al. Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report. Int J Psychiatry Med 2005;35:307–311.
40.	Takahashi M, Ohishi S, Katsumi C et al. Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report. Pharmacopsychiatry 2005;38:183–184.
41.	Macfarlane D, Fisher M. A combination of atypical antipsychotics and diabetic ketoacidosis. Pract Diabetes Care 2006;23:205–206. 
42.	Reddymasu S, Bahta E, Levine S et al. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. JOP 2006;7:303–305.
43.	Crown N, Feltham M, Bayliff CD. Olanzapine-Induced Diabetic Ketoacidosis Resulting in Prolongation of Hospital Stay: Clinical Outcome and Cost Issues. Can J Hosp Pharm 2007;60:192-194.
44.	Hamanaka S, Kamijo Y. New-onset diabetic ketoacidosis induced by the addition of perospirone hydrochloride in a patient treated with risperidone. Intern Med 2007;46:199– 200. 
45.	Kahn D, Bourgeois JA. Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine. J Clin Psychopharmacol 2007;27:397–400.
46.	Reis JS, Alvarenga T, Rosario PW et al. Diabetes mellitus associated with atypical antipsychotic medications: case report and review of the literature. Arq Bras Endocrinol Metabol 2007;51:488–493.
47.	Sato Y, Yasui-Furukori N, Kaneko S et al. New-onset diabetic ketoacidosis in a schizophrenic patient with multiple, autoimmune disease during treatment with risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:577–578. 
48.	Wong JO, Fu JC, Hung GB. Olanzapine-induced diabetic ketoacidosis in a Chinese man. Hong Kong Med J 2007;13:73-74.
49.	Dhamija R, Verma R. Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy. Diabetes Care 2008;31:50. 
50.	Taslipinar A, Yazici M, Kebapcilar L et al. A Case of Diabetic Ketoacidosis Associated with Risperidone Treatment. Turk J Endocrinol Metab 2008;12:97-98.
51.	Cho DY, Lindenmayer JP. Aripiprazole-induced agitation after clozapine discontinuation: a case report. J Clin Psychiatry 2009;70:141–143. 
52.	Niazy M, Neyyarapally T, Baidas G. Severe diabetic ketoacidosis precipitated by an atypical antipsychotic drug. Kuwait Med J 2009;41:240–242.
53.	Rashid J, Starer PJ, Javaid S. Pancreatitis and diabetic ketoacidosis with quetiapine use. Psychiatry (Edgmont) 2009;6:34–37.
54.	Kibbey KJ, Roberts AM, Nicholson GC. Diabetic ketoacidosis and elevated serum lipase in the setting of aripiprazole therapy. Diabetes Care 2010;33:96. 
55.	Watkins J, Ray S, Finch C. Aripiprazole-Induced Diabetic Ketoacidosis: Remaining Vigilant. Hospital Pharmacy 2011;46:432-435.
56.	Sa YK, Yang H, Jung HK et al. Olanzapine induced diabetic ketoacidosis and neuroleptic malignant syndrome with rhabdomyolysis: A case report. Endocrinol Metab 2013;28:70-75. 
57.	Tsolaki M, Symeonides G, Kazis A. Olanzapine induced diabetic ketoacidosis. Psychiatriki 2001;13:222–227.
58.	Fulbright A, Breedlove K. Complete resolution of olanzapineinduced diabetic ketoacidosis. J Pharm Pract 2006;1:255–258.
59.	Chellamuth P, Kong M, Gregory R. Ketosis-prone type 2 diabetes: an increasingly recognized entity. Pract Diabetes 2010;27:18–19.
60.	Lehner R, Dopke C, Cohen K et al. Outpatient treatment adherence and serious mental illness: a review of interventions. American Journal Of Psychiatric Rehabilitation [serial online] 2007;10:245-274. Doi: 10.1080/15487760601166324
61.	Emsley R, Chiliza B, Asmal L et al. The nature of relapse in schizophrenia. BMC Psychiatry 2013;13:50. 
62.	Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001;286:2547–2548.
63.	Koller EA, Doraiswamy PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841–852.
64.	Koller EA, Cross JT, Doraiswamy PM et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23:735–744.
65.	Liberty IF, Todder D, Umansky R et al. Atypical antipsychotics and diabetes mellitus: an association. Isr Med Assoc J 2004,6:276-279.
66.	Jin H, Meyer JM, Jeste DV. A typical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research 2004;71:195–212. 




Table 1. Treatment strategies including antipsychotic medication after antipsychotic-induced DKA 
Antipsychotic medication
Initial SGA(N=58)	Switch after SGA-induced DKA and outcome
Olanzapine (O) (N=26)	7 continued (in 5 cases with insulin, in 1 insulin + OHT, in 1e without OHT)19 discontinued: 1 re-challenge, then again discontinued - switched to Q, then discontinued  and switched to Cl (with insulin)        11 switched to: 5 R (3 cases with insulin, 2 cases with insulin + OHT)2 Z (no HT)1 Q (with insulin)1 A (with OHT)2 FGA (1 with insulin, 1 without OHT)2 with no antipsychotics (1 with insulin, 1 with OHT)5 N/R on antipsychotic therapy (without HT)   
Clozapine (Cl) (N=17)	2 continued (with OHT) - one after re-challenge15 discontinued: 2 re-challenge then again discontinued – 1 switched to FGA (with OHT) and 1 with no antipsychotics and HT9 switched to: 5 FGA (2 cases with insulin, 1 with insulin + OHT, 2 cases without HT)1 A then discontinued and switched to FGA (N/R HT)2 R one then discontinued and switched to FGA (with OHT)1 O (with OHT)                              4 N/R on antipsychotic therapy (2 with insulin, 2 without OHT)
Risperidone (R) (N=6)	1 continued (with insulin)5 discontinued:4 switched to: 2 FGA (with insulin)1 Q (with insulin)1 Z (without HT)1 N/R on antipsychotic therapy/HT 
Aripiprazole (A) (N=6)	1 continued (with insulin)5 discontinued: 1 switched to FGA (with insulin)1 without antipsychotics (with insulin)3 N/R on antipsychotic therapy (1 case with insulin; 1 with insulin + OHT; 1 N/R on HT )
Quetiapine (Q) (N=3)	3 discontinued:2 switched to: 1 FGA (with OHT)one FGA+R (with OHT)1 N/R on later antipsychotic therapy (without HT)

Abbreviations: O - olanzapine, R – risperidone, Q – quetiapine, A - aripiprazole, Cl –clozapine, HT- hypoglycemic therapy, OHT – oral hypoglycemic therapy, N/R – no record, SGA – second generation antipsychotic, FGA – first generation antipsychotic


Table 2. Recommended treatment strategies for patients at risk of antipsychotic-induced DKA

Psychiatrist: preventive measures
Obtain personal and family history of diabetesMonitor physical and laboratory measurements: BMI (baseline /monthly); abdominal girth (baseline/annually);  blood pressure (baseline/ 3 months/annually); fasting lipid profile (baseline/3 months/annually)Monitor fasting plasma glucose (baseline/one week/3 months/annually) Evaluate glycaemia immediately if the patient experiences polyuria, weight loss and thirst. Evaluate glycaemia  with two-hour oral glucose tolerance test with 75 g glucose in patients who (1) are overweight or obese; (2) have positive family history of diabetes; (3) personal history of gestational diabetes mellitus; (4)  laboratory values of glucose intolerance in medical history For patients with prediabetes, which according to ADA criteria denotes (1) patients with impaired fasting glucose (fasting glucose ≥5.6 mmol/l) and/or (2)  postprandial glucose intolerance (two-hour plasma glucose ≥7.8 mmol/L) and/or (3) HBA1c ≥5.7 percent (39mmol/mol) monitoring should include glycated hemoglobin Educate the patients and caregivers on symptoms and signs of diabetes
Diabetologist: acute treatment of patients with antipsychotic-induced DKA
Exclude the suspected agent in acute DKA Follow the treatment protocol as in DM type 1: obtain metabolic stabilization with multiple daily injections scheme;  ICA, IAA and GAD antibodies should be obtainedSuspect antipsychotic induced – DKA / DM type 2If antibodies are negative, discontinue the suspected SGA and gradually tapper insulin (first the short acting prandial one, then long acting one); introduce metformin to reduce insulin resistance
Multidisciplinary approach: post acute treatment of patients with antipsychotic-induced DKA
After discharge  these patients should be closely monitored by diabetologist, to obtain slow reduction of insulin dose and possibly omission of insulin based on glycemic values (first reduce prandial and then basal insulin)Introduce metformin after the probable insulin discontinuation has been successfully achieved if there are no contraindications for metformin. The maximal dose of 2g per day bid divided should be introduced until HbA1c reaches less than 6%, then reduce the daily dose of metformin by half, and monitor HbA1c in the next 3 to 6 months. If HbA1c is lower than 6%, metformin should be excluded from therapy.Revision of antipsychotic therapy should include switching to another SGA with lower propensity to DKA, unless it is already proven that the change of the basic antipsychotic will lead to significant deterioration of the patient’s psychiatric status.






Figure 1.  CONSORT diagram to report results of treatment options after antipsychotic-induced DKA




Figure 2. Hypoglycemic therapies after antipsychotic-induced DKA







Table 1. Case reports of antipsychotic-induced DKA
No	Authors, date	Patientage, sex, ethnicity diagnosis	Drug	Dose mg/day (duration)	CPZE	Polypharmacy	Psycho-pharmacotherapy after DKA	Re-challenge	Therapyat discharge	HTat follow up
1	Koval et al. (1994)11	34, female, Afro-AmSch	Cl	250 (6 weeks)	180.1	lithium,benztropine	haloperidol,lithium,benztropine	On day 24-29,then discontinued	haloperidol,insulin	OHT, then diet
2	Kostakoglu et al. (1996)12	42, male, N/R,Psychosis	Cl	350  (4 weeks)	252.2	No	Cl discontinued	No	fluphenazine decanoate, diet	Diet
3	Peterson & Byrd (1996)13	46, male, Afro-AmSch	Cl	500  (5 weeks)	362.3	lithium, bethanechol,verapamil	Cl discontinued	No	antipsychotic  N/R,insulin	Insulin for 2 years
4	Ai et al. (1997)14	30, male, Afro-CaribSch	Cl	300  (5 months)	216.2	No	O	No	O, OHT	OHT
5	Pierides (1997)15	50, male, N/R,Sch	Cl	300  (10 days)	216.2	flupenthixol decanoate 80 mg	Cl discontinued	No	fluphentixoldecanoate,  insulin	N/R
6	Popli et al. (1997)16	32, male, Afro-AmSch, AbP	Cl	425  (8 weeks)	306.2	ephedrine	Cl discontinued	Yes 	Cl,  OHT	4 monthsOHT
7	Wirshing et al. (1998)17	32, male, Afro-AmSch	Cl	400 (18 months)	288.2	No	Cl	Continued	Cl,  OHT	OHT
8	Wirshing et al. (1998)17	41, male, Afro-AmSch	Cl	200  (5 weeks)	144.1	No	R	No	R, OHT	4 weeksOHT
9	Colli et al. (1999)18	31, male, WhiteSch	Cl	200  (3 months)	144.1	No	Cl discontinued	After 2 months, but discontinued after 3 days	carbamazepine,diet	Diet
10	Gatta et al. (1999)19	31, male, WhiteSch	O	10  (3 months)	188	FGA	FGA	No	FGA, diet	8 monthsdiet
11	Goldstein et al. (1999)20	42, female, WhiteSch	O	10  (6 months)	188	valproic acid	Q	No	Q, insulin	Insulin
12	Goldstein et al. (1999)20	40, female, WhiteSch	O	10 (18 months)	188	No	R	No	R, insulin	No HT
13	Mohan et al. (1999)21	30, male, Afro-AmSch	Cl	325 (3 months)	234.2	No	R, then discontinued	No	FGA, OHT	2 yearsOHT
14	Smith et al. (1999)22	40, maleN/R	Cl	N/R	-	No	FGA	No	FGA, insulin	Insulin
15	Croarkin et al. (2000)23	42, male, WhiteN/R	R	4 (months)	333.3	fluoxetine, trazodone	Q,  fluoxetine	No	Q, insulin	N/R
16	Rigalleau et al. (2000)24	41, male, WhitePsychosis	O	N/R (3 months)	-	No	O discontinued	No	antipsychotic  N/R, no HT	No HT
No	Authors/ Reference	Patientage, sex, ethnicity diagnosis	Drug	Dose mg/day (duration)	CPZE	Polypharmacy	Psycho-pharmacotherapy after event	Re-challenge	Therapyat discharge	HTat follow up
17	Avram (2001)25	33, male, WhiteSch	Cl	100  (8 months)	72.1	sertraline,ranitidine, trihexyphenidil	Cl discontinued	No	antipsychotic  N/R, insulin	2 months insulin
18	Muench & Carey (2001)26	38, male, WhiteSch	O	20  (12 months)	376	valproic acid,venlafaxine,propranolol,atorvastatine	O	Continued	O, insulin	2 months insulin
19	Nicolai (2001)27	33, male, AsianSch	Cl	4501000 (4 years)	324.4-	Yes (valproate)	haloperidol	No	haloperidol,no HT	No HT
20	Ragucci (2001)28	46, female, Afro-AmBAD	O	15  (14 months)	282	valproic acid,carbamazepine,hydrochlorthiazide/ triamteren,estrogen	R	No	R, carbamazepine,insulin, OHT	4 monthsinsulin, OHT
21	Selva & Scott (2001)29	16, female, Afro-AmN/R	OR	15 (6 months)N/R (6 months)	282-	venlafaxine	O discontinuedR ½ dose continued	R continued	R,  venlafaxine,none HT	6 months
22	Wirshing et al. (2001)30	52, Afro-AmSch	R	8  (15 months)	666.6	No	R	Continued	R, insulin	Insulin
23	Johnson et al. (2002)31	49, male, WhiteSch	O	20 (11 months)	376	No	O	Continued	O,  insulin	No HT
24	Waldman & Yaren (2002)32	33, male, AborigineN/R	O	30  (3 months)	564	No	O discontinued, Q, then discontinued	After one month, but discontinued after 2 days	Cl, insulin	OHT
25	Wilson et al. (2002)33	48, male, Afro-AmPsychosis	O	30 (10 months)	564	No	O	Continued	O, insulin	Insulin
26	Wilson et al. (2002)33	26, female, Afro-AmSch, AbP	ClR	125 (5 days)3 (6 weeks)	90250	lithium, clonazepam, venlafaxine	Cl continued,R discontinued	Cl continued	Cl, insulin	Diet
27	Wilson et al. (2002)33	33, Afro-AmSchA	OCl	10 (1 month)550  (6 weeks)	188396.3	Yes (unspecified)	Cl, O	Continued	Cl, O,insulin	Insulin
28	Tavakoli & Arguisola (2003)34	35, male WhiteBAD, AbP	O	5 (18 months)	94	valproic acid, venlafaxine	No	No	valproic acid, venlafaxine, insulin	Insulin
29	Tsuchiyama et al. (2003)35	28, male, AsianSch	O	10 (1 month)	188	No	O	Continued	O,no HT	No HT
30	Ananth et al.(2004)36	46N/R	R	3 (2 years)	250	lithium	No	No	lithium, no HT	2 years, No HT
No	Authors/ Reference	Patientage, sex, ethnicity, diagnosis	Drug	Dose mg/day (duration)	CPZE	Polypharmacy	Psycho-pharmacotherapy after event	Re-challenge	Therapy at discharge	HTat follow up
31	Meyer et al.(2004)37	48, male, White,Sch	Q	800 (4 weeks)	455.8	haloperidol	haloperidol	No	R,  haloperidol,lithium, OHT	N/R
32	Church et al. (2005)38	34, female, Afro-AmSch	AO	30 (4 days)20  (years)	376.4376	diazepam, metformin, rosiglitazone	A discontinuedO continued	O continued	O,diazepam,insulin	N/R
33	Dibben et al. (2005)39	51, female, WhiteSch	Q	400 (2 years)	227.9	lithium,thyroxine,simvastatine, aspirin	Q discontinued	No	antipsychotic  N/R, diet	No HT
34	Takashashi et al. (2005)40	72, male, AsianN/R	Q	50 (14 days)	28.5	tiapride	haloperidol	No	haloperidol,valproate, OHT	4 monthsOHT
35	Mcfarlane & Fisher (2006)41	33Sch	QO	600 (4 weeks)10 (2 years)	341.9188	folic acid	O discontinued, Q	Q continued	Q, insulin	Insulin
36	Reddymasu et al. (2006)42	33, female, Afro-Am Sch	A	N/R (18 months)	-	No	haloperidol	No	haloperidol,insulin	Insulin
37	Crown et al.(2007)43	MaleN/R	O	10 (18 months)	188	paroxetine, atenolol, clonazepam, hydrochlortiazide	No	No	no antipsychotic, OHT	N/R
38	Hamanaka & Kamijo (2007)44	32, male, AsianSch	PH R	8 (9 days)4 (3 years)	-333.3	Yes(unspecified)	PH/R discontinued	Yes (R after 2 weeks)	R, diet	N/R
39	Kahn & Bourgeois (2007)45	29, male, Afro-AmSch, AbP	O	30	564	alprazolam	A	No	A, OHT	1 month OHT
40	Reis et al.  (2007)46	28 Sch	CL	150  (1 month)	108.1	No	Cl discontinued	No	antipsychotic  N/R, no HT	5 monthsno HT
41	Sato et al. (2007)47	46, female, AsianSch	R	3 (4 months)	250	levomepromazine	levomepromazine	No	levomepromazineinsulin	Insulin
42	Wong et al. (2007)48	22, male, AsianSch	O	10 (15 months)	188	valproic acid	haloperidol	No	haloperidol, valproic acid, insulin	1 yearinsulin
43	Dhamija & Verma (2008)49	12, male, WhiteN/R	A	N/R (6 months)	-	No	A discontinued	No	antipsychotic  N/R,HT N/R	N/R
44	Taslipinar et al. (2008)50	26, maleSch	R	6 (5 months)	500	No	Z	No	Z, diet	Diet
										
No	Authors/ Reference	Patientage, sex, ethnicity diagnosis	Drug	Dose mg/day (duration)	CPZE	Polypharmacy	Psycho-pharmacotherapy after event	Re-challenge	Therapy at discharge	HTat follow up
45	Cho and Lindenmayer (2009)51	45, female, Afro-AmSch, AbP	Cl	N/R (17 months)	-	haloperidol, valproic acid, nortriptyline	A, then discontinued	No	haloperidol,molindone,N/R HT	N/R
46	Niazy et al(2009)52	28, maleSch	O	N/R (18 months)	-	No	R	No	R, insulin	No HT
47	Rashid et al.(2009)53	30, femaleSch	QZ	200 (2 months)160 (9 months)	114255.5	Yes(unspecified)	haloperidol	No	haloperidol,HT N/R	N/R
48	Kibbey et al.(2010)54	30, maleSch	A	20  (12 months)	251	No	A	Continued	A,insulin	N/R
49	Watkins et al.(2011)55	55, male, Afro-AmN/R	A	10 (6 months)	125.5	sertraline	A discontinued	No	sertraline, insulin	N/R
50	Sa et al. (2013)56	29, maleN/R	O	30 (32 months)	564	valproic acid, clonazepam, lorazepam	Z	No	Z, diet	No
51	Vuk et al. (2017)8	33, male, WhiteSch	Cl	200 (2 weeks)	144.1	haloperidol, bisoprolol	haloperidol,amisulpride	No	haloperidol,amisulpride,insulin, OHT	1 monthOHT
52	Vuk et al. (2017)8	27, male, WhiteSch	O	20 (years)	376	No	O	Continued	O, insulin	Lost for follow up
53	Vuk et al. (2017)8	46, male, WhiteSch	O	10 (3 years)	188	No	R	No	R,insulin	2 yearsOHT
54	Lyndenmayer & Patel (1999)10	50, male, Afro-AmSch	O	30 (8 months)	564	Yes(unspecified)	O discontinued	No	antipsychotic  N/R, no HT	N/R
55	Seaburg et al.(2001)10	27, male, Afro-AmSch	O	10 (2 years)	188	valproic acid	O continued,valproate discontinued,	O continued	O,insulin, OHT	N/R
56	Straker et al. (2002)10	44, female, Afro-AmSch	O	25 (7 weeks)	469.9	Yes(unspecified)	O discontinued	No	antipsychotic  N/R, diet	N/R
57	Tsolaki et al.(2002)10,57	80, female, WhiteN/R	O	N/R (10 months)	-	paroxetine	O discontinued	No	antipsychotic  N/R, no HT	N/R
58	Lafayette (2003)10	28, female, HispanicSch	Cl	150 (10 weeks)	-	valproate	Cl discontinued	No	antipsychotic N/R, diet	N/R
59	Howes & Rifkin (2004)10	41, femaleSchA	O	20 (3.5 months)	108.1	Yes(unspecified)	O	Continued	O, insulin	N/R
60	Babu et al. (2005)10	15, femaleBAD	A	N/R (4 months)	-	Yes(unspecified)	A discontinued	No	antipsychotic  N/R, insulin	N/R
No	Authors/ Reference	Patientage, sex, ethnicity diagnosis	Drug	Dose mg/day (duration)	CPZE	Polypharmacy	Psycho-pharmacotherapy after event	Re-challenge	Therapy at discharge	HTat follow up
61	Fullbright & breedlove (2006)10,58	42,  Afro-AmSch	O	40 (40 days)	751.9	Yes(unspecified)	Z	No	Z, no HT	N/R
62	Kyriazis et al. (2006)10	33, male, WhiteN/R	O	20 (4 months)	376	N/R	O discontinued	No	antipsychotic  N/R, diet	N/R
63	Varma et al.(2007)10	35, femaleBAD	O	10 (6 weeks)	188	Yes(unspecified)	R	No	R, insulin	N/R
64	Makhzoumi et al. (2008)10	44, male AfroAmSch	A	30 (17 days)	376.4	Yes(unspecified)	A discontinued	No	Antipsychotic, N/R,insulin, OHT	N/R
65	Chellamuth et al (2010)10,59	42, male AsianSch	R	N/R (depot)	-	N/R	haloperidol	No	haloperidol,insulin	N/R





